Glucagon-like peptide 1--a cardiologic dimension.
Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.
Treiman
Marek
M
Department of Biomedical Sciences and The Danish National Foundation Research Center for Heart Arrhythmia, University of Copenhagen, Copenhagen, Denmark. m.treiman@mfi.ku.dk
Elvekjaer
Mikkel
M
Engstrøm
Thomas
T
Jensen
Jan Skov
JS
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use*; D006331:Heart Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome; D014664:Vasodilation / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects
D002317:Cardiovascular Agents; D052216:Glucagon-Like Peptide 1